Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes - Wikidata - wikimedia - TriplyDB

Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes

Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes

http://www.wikidata.org/entity/Q28193220

about

sameAs

Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey o How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England A clearly visible V wave in the pulmonary artery pressure curve caused by severe mitral valve regurgitation Patients with acute coronary syndrome should start a statin while still in hospital.Knowledge, attitudes and current practice of Jordanian family physicians about prescribing aspirin in primary and secondary prevention of vascular diseases: a self-reported survey.Prescription at discharge of recommended treatments for secondary prevention in patients with ST-segment elevation myocardial infarction according to reperfusion strategies. Results from the IN-ACS outcome study

P2860

Q24804642-938FCAF5-B403-409E-BFCB-CD0E5D0E6E86 Q28196775-8F94696D-4EFD-44CF-A51F-97C6E2FC5A5F Q28217880-A2A38411-1843-4687-9901-6F7F29E023B3 Q28221444-9D6F6F7E-1594-463B-B0A5-4CF1631B2601 Q36917392-08DE6519-0F6D-473C-A2B3-F9764EED3F16 Q42700220-428B036C-2B3F-4BF9-B914-6E9A2C843464 Q51749042-49D43E94-B78B-48C3-9D16-1EAFFD15BC07 Q56991534-4D4C7F65-65C3-459E-A5C2-8F8165882188

P2860

Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes

http://www.wikidata.org/entity/Q28193220

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Impact of availability and use ...... after acute coronary syndromes

@ast

Impact of availability and use ...... after acute coronary syndromes

@en

Impact of availability and use ...... after acute coronary syndromes

@nl

type

label

Impact of availability and use ...... after acute coronary syndromes

@ast

Impact of availability and use ...... after acute coronary syndromes

@en

Impact of availability and use ...... after acute coronary syndromes

@nl

prefLabel

Impact of availability and use ...... after acute coronary syndromes

@ast

Impact of availability and use ...... after acute coronary syndromes

@en

Impact of availability and use ...... after acute coronary syndromes

@nl

P1433

Q28193220-157990BF-2E94-4D81-87BF-500CDB00DA82

P1476

Q28193220-127174AB-FA0D-4536-98EF-B7BB280A9976

P2093

Q28193220-084E4242-B7AF-47EB-8A96-1744930A1858

Q28193220-2F4CB207-182C-4E66-BD15-E0B7F2C91BB5

Q28193220-619B287E-34C0-4AC8-9235-4EE3071B7FFF

Q28193220-7D715645-B731-4E11-8AED-25888C2EB4E5

Q28193220-B04A1C70-773B-490A-8D3F-D4813E7C1678

Q28193220-D04D898F-F524-4F12-B059-933B3224669C

Q28193220-D25F62AB-9056-4063-8070-D0F5F329A6FC

P2860

Q28193220-11485BDE-C805-4065-AD53-37AC0324744D

Q28193220-32404783-AAF6-4248-A7B0-7BDF1A9993B6

Q28193220-32422321-83EF-46A8-8B51-FE826E8DF4F5

Q28193220-3CBE007C-0C2F-4C29-B257-EE3164728051

Q28193220-425DF55A-9D1F-48A1-B940-2DE388B7856B

Q28193220-427E2BFB-4815-43C0-8953-E738A14F4647

Q28193220-77C55CE3-61D9-4CEB-BA69-AD2DE8CFB5F8

Q28193220-9846822E-254E-44F6-B46D-80B6B1DA0A75

Q28193220-A5D95046-58EA-4583-8977-495F70B94543

Q28193220-BDE92600-E2BD-4AC0-A93C-2561182C3DDB

P304

Q28193220-332EA492-E0BA-445F-BC5E-4E818F6FBE64

P31

Q28193220-53BE47F8-3307-4C29-A01D-B04D6B7059DB

P356

Q28193220-4E5A2BF9-D3A0-4E68-8B6C-9913AC3BE04B

P407

Q28193220-C65804D9-0143-4F34-9B6A-D8FABC740D43

P433

Q28193220-3C1361C8-A028-45DB-A241-A52B9C44F71E

P478

Q28193220-B1F10625-050E-496B-8970-1023CD4BCF39

P50

Q28193220-D555F179-37B2-4A42-A1D1-F6EEE79D28AC

P577

Q28193220-6A4ECC0A-D52C-4637-8DAE-7A5B8B1D0876

P5875

Q28193220-22D712F5-F3DF-45CE-AA00-AD6383AC0E58

P698

Q28193220-56B8E443-E811-448F-B569-D86965A5F1F9

P921

Q28193220-12529D48-B84F-42DA-91A4-95560497270F

P932

Q28193220-3575C0C0-73FD-4362-8E94-2E609A05C7CD

P356

P1433

P1476

Impact of availability and use ...... after acute coronary syndromes

@en

P2093

A P Maggioni

http://www.w3.org/2001/XMLSchema#string

B Iung

http://www.w3.org/2001/XMLSchema#string

D Cokkinos

http://www.w3.org/2001/XMLSchema#string

J Deckers

http://www.w3.org/2001/XMLSchema#string

K A A Fox

http://www.w3.org/2001/XMLSchema#string

L J Feldman

http://www.w3.org/2001/XMLSchema#string

U Keil

http://www.w3.org/2001/XMLSchema#string

P2860

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

P304

20-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HEART.88.1.20

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Gabriel Steg

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11306564

http://www.w3.org/2001/XMLSchema#string

P698

12067934

http://www.w3.org/2001/XMLSchema#string

P921

P932

1767154

http://www.w3.org/2001/XMLSchema#string